Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Drug Profile

Aminolevulinic acid - Nobelpharma/SBI Pharmaceuticals

Alternative Names: 5-ALA - Nobelpharma; Alabel; Alaglio; NPC-07

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SBI Pharmaceuticals Co Ltd
  • Developer Kyoto University; Nobelpharma; SBI Pharmaceuticals Co Ltd
  • Class Amino acids; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Skin disorder therapies; Small molecules
  • Mechanism of Action Photosensitisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bladder cancer; Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma
  • Preregistration Bladder cancer
  • Phase II Solid tumours
  • Clinical Phase Unknown Anaemia; Cognition disorders

Most Recent Events

  • 22 Jun 2017 SBI Pharmaceuticals completes a phase I trial in Healthy volunteers in Japan (UMIN000022825)
  • 13 Mar 2017 Aminolevulinic acid licensed to Chugai Pharmaceutical in Japan for Bladder cancer (Diagnosis)
  • 13 Mar 2017 Preregistration for Bladder cancer (Diagnosis) in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top